X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with SHASUN PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs SHASUN PHARMA - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA SHASUN PHARMA AUROBINDO PHARMA/
SHASUN PHARMA
 
P/E (TTM) x 13.6 123.9 11.0% View Chart
P/BV x 3.0 8.5 34.6% View Chart
Dividend Yield % 0.4 0.2 181.8%  

Financials

 AUROBINDO PHARMA   SHASUN PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
SHASUN PHARMA
Mar-14
AUROBINDO PHARMA/
SHASUN PHARMA
5-Yr Chart
Click to enlarge
High Rs80994 858.8%   
Low Rs50446 1,105.3%   
Sales per share (Unadj.) Rs281.1214.2 131.2%  
Earnings per share (Unadj.) Rs41.45.3 775.0%  
Cash flow per share (Unadj.) Rs50.915.8 321.6%  
Dividends per share (Unadj.) Rs2.501.00 250.0%  
Dividend yield (eoy) %0.41.4 26.6%  
Book value per share (Unadj.) Rs199.453.3 373.8%  
Shares outstanding (eoy) m585.8856.62 1,034.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.30.3 715.7%   
Avg P/E ratio x15.913.1 121.2%  
P/CF ratio (eoy) x12.94.4 292.0%  
Price / Book Value ratio x3.31.3 251.3%  
Dividend payout %6.018.7 32.3%   
Avg Mkt Cap Rs m384,6303,958 9,718.4%   
No. of employees `00017.3NA-   
Total wages/salary Rs m21,3082,164 984.9%   
Avg. sales/employee Rs Th9,500.7NM-  
Avg. wages/employee Rs Th1,229.4NM-  
Avg. net profit/employee Rs Th1,397.9NM-  
INCOME DATA
Net Sales Rs m164,66612,127 1,357.9%  
Other income Rs m1,020229 444.6%   
Total revenues Rs m165,68612,356 1,340.9%   
Gross profit Rs m37,7181,009 3,737.9%  
Depreciation Rs m5,580594 940.0%   
Interest Rs m777415 187.2%   
Profit before tax Rs m32,380230 14,096.8%   
Minority Interest Rs m310-   
Prior Period Items Rs m00 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,183-73 -11,252.3%   
Profit after tax Rs m24,229302 8,019.7%  
Gross profit margin %22.98.3 275.3%  
Effective tax rate %25.3-31.7 -79.8%   
Net profit margin %14.72.5 590.6%  
BALANCE SHEET DATA
Current assets Rs m121,8786,884 1,770.4%   
Current liabilities Rs m86,8068,456 1,026.6%   
Net working cap to sales %21.3-13.0 -164.3%  
Current ratio x1.40.8 172.5%  
Inventory Days Days13062 210.7%  
Debtors Days Days68108 63.6%  
Net fixed assets Rs m81,0374,970 1,630.5%   
Share capital Rs m586113 517.1%   
"Free" reserves Rs m116,2182,875 4,042.5%   
Net worth Rs m116,8043,020 3,867.4%   
Long term debt Rs m4,5121,817 248.3%   
Total assets Rs m211,05213,347 1,581.3%  
Interest coverage x42.71.6 2,746.5%   
Debt to equity ratio x00.6 6.4%  
Sales to assets ratio x0.80.9 85.9%   
Return on assets %11.85.4 220.5%  
Return on equity %20.710.0 207.4%  
Return on capital %27.413.3 205.3%  
Exports to sales %046.4 0.0%   
Imports to sales %014.2 0.0%   
Exports (fob) Rs mNA5,622 0.0%   
Imports (cif) Rs mNA1,728 0.0%   
Fx inflow Rs m80,7275,843 1,381.7%   
Fx outflow Rs m34,7002,173 1,596.8%   
Net fx Rs m46,0273,669 1,254.3%   
CASH FLOW
From Operations Rs m19,548398 4,916.5%  
From Investments Rs m-19,570-1,635 1,196.9%  
From Financial Activity Rs m8,6421,309 660.4%  
Net Cashflow Rs m8,92271 12,531.0%  

Share Holding

Indian Promoters % 54.1 39.2 138.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 3.6 220.8%  
FIIs % 27.7 17.6 157.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 39.6 25.8%  
Shareholders   69,601 20,750 335.4%  
Pledged promoter(s) holding % 8.6 12.3 69.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   GLENMARK PHARMA  FULFORD INDIA  WYETH LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 267 Points Lower; Metal and Capital Goods Stocks Witness Huge Selling(Closing)

India share markets continued to witness selling pressure during closing hours and ended their day deep in the red. At the closing bell, the BSE Sensex stood lower by 267 points (down 0.7%).

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

The Perfect Stock in the Rebirth of India(The 5 Minute Wrapup)

Aug 8, 2019

This debt-free, well-managed company is all set to soar.

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Super investor Pulak Prasad is Buying Stocks Big Time...and You Should Too(The 5 Minute Wrapup)

Aug 9, 2019

Here's why the relentless correction in the Indian stock markets has not unnerved the big investors.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Qatar is Rearing Cows...this is Good News for India

Aug 9, 2019

Qatar has turned around after the Saudi embargo. This is good news for India.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 21, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS